Healthcare Global Enterprises Limited (HCG) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Healthcare Global Enterprises Limited stock ₹68.04, price ₹600, that is 88.7% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally.
Show moreShow less
The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling.
It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services.
In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care.
Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand.
HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Stock analysis
Healthcare Global Enterprises Limited (HCG) currently trades at ₹600.25, while our model-based Fair Value estimate is ₹68.04, 89% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ₹131.99 per share, and 0 of the 23 models we run sit above the ₹600.25 price.
Bear case: the Growth Earnings group reads lowest at ₹22.56, and 23 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹50.02 (bear) to ₹103.01 (bull), the price of ₹600.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Healthcare Global Enterprises Limited reported revenue of ₹25.4B in FY2026 versus ₹14.0B in FY2022, a compound +16.1%/yr. Reported net income was ₹138M in FY2026, compounding −28.9%/yr from FY2022.
Key figures
Market cap ₹86.0B (≈ $916M) Small · P/E ratio 387.3 · P/S ratio 3.30 · EPS (TTM) ₹1.55 · Net margin 0.9% · Return on equity 1.9% · Return on assets (EBIT) 28.5% (5-year average) · Operating margin 7.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 21% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −89%, HCG screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹15.11 to ₹275.57). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear₹50.02Fair Value ₹68.04Bull₹103.01
Price ₹600.25 · Downside -88.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹0.9427 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Start year 2021 (pandemic). Over 10 years: +15.8% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−24.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−24.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−24.7% vs −3.4%, slowing
Profit margin 2011 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 9%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+65.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +58.6% a year for the price and +8.2% for the forecasts.
Compare Healthcare Global Enterprises Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks
Beats the industry median on 1/13 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−88.7% · Bottom 25%
Profitability
Return on equity (12 months)1.9% · Below median
Return on assets0.6% · Bottom 25%
Net margin (12 months)1.4% · Bottom 25%
Operating margin (12 months)7.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)13.4% · Above median
Balance sheet
Debt / equity0.45× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Healthcare Global Enterprises Limited Fair Value". https://www.fairvalue-calculator.com/stock/HCG
Frequently asked questions
Is Healthcare Global Enterprises Limited (HCG) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ₹68.04 versus a price of ₹600.25, about 89% lower (overvalued).
What is the fair value of HCG?
Our model-based fair value for Healthcare Global Enterprises Limited is ₹68.04 (as of Nov 5, 2026), built from audited fundamentals. The current price: ₹600.25.
What is the quality score of HCG?
Healthcare Global Enterprises Limited has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Healthcare Global Enterprises Limited (HCG)?
Our model-based price target is the fair value of ₹68.04 (as of Nov 5, 2026) from 23 valuation models. Cautious scenario ₹50.02, optimistic scenario ₹103.01. It is a calculation from audited fundamentals, not an analyst target.
What is the Healthcare Global Enterprises Limited stock forecast for 2026?
Our models put fair value at ₹68.04, about 89% lower versus a price of ₹600.25 (overvalued). Cautious scenario ₹50.02, optimistic scenario ₹103.01. The calculation is refreshed regularly with new filings.
What is the revenue of Healthcare Global Enterprises Limited (HCG)?
Healthcare Global Enterprises Limited reported trailing-twelve-month revenue of about ₹26.3B (latest available figure, as of Nov 5, 2026).
What growth is priced into Healthcare Global Enterprises Limited (HCG)?
For today's price to be fair in a discounted-cash-flow model, Healthcare Global Enterprises Limited would have to grow free cash flow by +65.2 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.2 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of HCG use?
Our models discount Healthcare Global Enterprises Limited at 13.9 %: a base by market capitalisation (small), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Healthcare Global Enterprises Limited that is +65.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has Healthcare Global Enterprises Limited (HCG) delivered so far?
Over the past 5 years revenue at Healthcare Global Enterprises Limited grew +20.2 % a year. The price currently implies free-cash-flow growth of +65.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Healthcare Global Enterprises Limited (HCG) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Healthcare Global Enterprises Limited (+65.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Healthcare Global Enterprises Limited (HCG)?
The free-cash-flow yield on the price is 0.64 %: that much free cash flow Healthcare Global Enterprises Limited produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Healthcare Global Enterprises Limited (HCG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Healthcare Global Enterprises Limited it is ₹68.04 per share (as of Nov 5, 2026), against a price of ₹600.25. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Healthcare Global Enterprises Limited stock overvalued or undervalued in 2026?
As of Nov 5, 2026, HCG trades above its calculated fair value: price ₹600.25, fair value ₹68.04, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HCG?
No. The price is what the market pays today (₹600.25); the fair value is what the company's own numbers justify (₹68.04). For Healthcare Global Enterprises Limited the two are ₹532.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Healthcare Global Enterprises Limited worth?
The market values Healthcare Global Enterprises Limited at about ₹86.0B (market capitalisation, as of Nov 5, 2026). Per share that is ₹600.25; our models calculate a fair value of ₹68.04 per share.
What do the bullish and bearish scenarios say about HCG?
Our models span a range for Healthcare Global Enterprises Limited: cautious scenario ₹50.02, base ₹68.04, optimistic ₹103.01 per share (as of Nov 5, 2026, price ₹600.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HCG?
Healthcare Global Enterprises Limited trades at a price-to-earnings ratio of 387.3 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹68.04 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2026), reported earnings: 121.5. Other multiples: P/B 6.5, P/S 5.4, EV/EBITDA 29.0.
How solid is the balance sheet of Healthcare Global Enterprises Limited (HCG)?
Balance-sheet figures for Healthcare Global Enterprises Limited (as of Nov 5, 2026): return on equity 1.9%, debt of 0.45 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is HCG from its 52-week high?
Healthcare Global Enterprises Limited trades at ₹600.25, about 21% below its 52-week high of ₹762.60 and 15% above the low of ₹521.75 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ₹68.04 is for.
Which stocks are comparable to Healthcare Global Enterprises Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Healthcare Global Enterprises Limited stock attractive at the current price?
The data as of Nov 5, 2026: price ₹600.25, calculated fair value ₹68.04 (−89%), Quality Score 43/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HCG calculated?
We run Healthcare Global Enterprises Limited through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹68.04 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Healthcare Global Enterprises Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Healthcare Global Enterprises Limited (HCG)?
The closing price on Nov 6, 2026 was ₹600.25. Our model-based fair value is ₹68.04, about 89% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Healthcare Global Enterprises Limited right now?
The price sits above even our optimistic bull case (₹103.01). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹50.02 to ₹103.01) leaves room in how you read the outcome.
Where does the earnings growth of Healthcare Global Enterprises Limited (HCG) come from?
Earnings per share at Healthcare Global Enterprises Limited grew +6.2 % a year from 2015 to 2026. Broken into its drivers: revenue per share +8.2 %, EBIT margin −3.9 %, tax rate +0.6 %, residual (interest, one-offs) +1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Healthcare Global Enterprises Limited
How large is the market capitalisation of Healthcare Global Enterprises Limited (HCG)?
The market capitalisation of Healthcare Global Enterprises Limited is ₹86.0B (≈ $916M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Healthcare Global Enterprises Limited (HCG)?
The price-to-sales ratio of Healthcare Global Enterprises Limited is 3.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Healthcare Global Enterprises Limited (HCG)?
Earnings per share at Healthcare Global Enterprises Limited are ₹1.55 (price ÷ EPS = P/E 387.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Healthcare Global Enterprises Limited (HCG)?
The net margin of Healthcare Global Enterprises Limited is 0.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Healthcare Global Enterprises Limited (HCG)?
The return on equity (ROE) of Healthcare Global Enterprises Limited is 1.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Healthcare Global Enterprises Limited (HCG)?
On an EBIT basis the return on assets of Healthcare Global Enterprises Limited is 28.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Healthcare Global Enterprises Limited (HCG)?
The operating margin of Healthcare Global Enterprises Limited is 7.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Healthcare Global Enterprises Limited (HCG)?
Revenue at Healthcare Global Enterprises Limited is growing +13.4% versus a year earlier (3y avg +14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Healthcare Global Enterprises Limited (HCG)?
Earnings per share at Healthcare Global Enterprises Limited are growing +171% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Healthcare Global Enterprises Limited (HCG) carry?
The net debt of Healthcare Global Enterprises Limited is ₹12.0B (fiscal year 2026, ≈ 21.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Healthcare Global Enterprises Limited in the live analysis
One click puts Healthcare Global Enterprises Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026